Invitation to presentation of Q-linea’s Interim Report Q2-2019 on July 18, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 18, 2019 at 07:30 a.m. CET.

Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on July 18, at 13:00 – 14:00 p.m CET.

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – June 2019 followed by a Q&A-session.
  

To participate, please call any of the following phone numbers from:
Sweden: + 46 8 519 993 83
UK: + 44 333 300 9262
US: + 1 646 722 4956
  

Webcast: https://tv.streamfabriken.com/q-linea-q2-2019
  

For more information, please contact:

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0)70-600 15 20

The information was submitted for publication at 13:00 CET on July 11, 2019.
  

About Q-linea

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Tags:

About Us

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Subscribe

Documents & Links